Black Diamond Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
BDTX$1.60-14.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)
(in thousands, except share and per share data)
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2026 | 2025 | |
| License revenue | $— | $70,000 |
| Operating expenses: | ||
| Research and development | $7,003 | $10,506 |
| General and administrative | 4,256 | 4,964 |
| Total operating expenses | 11,259 | 15,470 |
| Income (loss) from operations | (11,259) | 54,530 |
| Other income (expense): | ||
| Interest income | 1,023 | 595 |
| Other income (expense) | 1,200 | 1,417 |
| Total other income (expense), net | 2,223 | 2,012 |
| Net income (loss) | $(9,036) | $56,542 |
| Net income (loss) per share - basic | $(0.16) | $1.00 |
| Net income (loss) per share - diluted | $(0.16) | $0.98 |
| Weighted average common shares outstanding - basic | 57,233,413 | 56,663,798 |
| Weighted average common shares outstanding - diluted | 57,233,413 | 57,673,099 |
| Comprehensive income (loss): | ||
| Net income (loss) | $(9,036) | $56,542 |
| Other comprehensive income (loss): | ||
| Unrealized gain (loss) on investments, net | (137) | (43) |
| Comprehensive income (loss) | $(9,173) | $56,499 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.